The Latest NHS-Approved Weight-Loss Medication: Semaglutide

Semaglutide (Wegovy, Novo Nordisk) is a new drug that can be used to support people to reduce their weight by over 10%. Wegovy has been approved by NICE and will be made available on the NHS for those who meet the criteria.

Clinical trial evidence shows that people lose more weight with Semaglutide (Wegovy) alongside supervised weight loss coaching than with drug support alone. Wegovy can help to regulate your appetite and help to reduce cravings and if used alongside a reduced-calorie diet and increased physical activity, it can help to achieve sustained weight loss.

At ABL Health, we understand that the causes of weight gain are complex and that weight is a chronic and recurrent disease therefore, weight management support needs to be diverse and bespoke to the needs of people living with obesity. Research shows us that people generally believe obesity is caused by factors within a person’s control, focusing on diet and exercise without recognition of, for instance, social and environmental determinants. This can lead to shame and guilt which makes achieving a healthier lifestyle, even harder.

Wegovy gives us the opportunity to provide further clinical options, for eligible clients, alongside our evidence-based programme to support people living with obesity to improve their health and well-being. ABL Health is currently prescribing Saxenda to all eligible clients and will do the same when Wegovy is available around Spring time.

Wegovy will be available on the NHS as a possible treatment for managing weight alongside a reduced-calorie diet and increased physical activity in adults if:

It is used for a maximum of 2 years, and within a specialist multidisciplinary weight management service.


You have at least 1 weight-related medical condition.


  • a body mass index (BMI) of at least 35.0 kg/m2, or
  • a BMI of 30.0 kg/m2 to 34.9 kg/m2 and meet NICE’s criteria for referral to specialist weight management services.
  • Lower BMI thresholds (usually reduced by 2.5 kg/m2) are used for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.

ABL Health welcomes the recent NICE technical appraisal which brings us a step closer to supporting overweight or obese individuals in a more holistic and supportive manner. 

For more information, please see the NICE article below:

More Posts